PTO/SB/30 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OCT 2 7 2005

NOTE:

REQUEST **FOR**

UED EXAMINATION (RCE) TRANSMITTAL

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.								
REQUEST	Application Number	10/622,479						
FOR	Filing Date	July 21, 2003						
INUED EXAMINATION (RCE)	First Named Inventor	Tsuyoshi SHIBATA						
TRANSMITTAL	Group Art Unit	2853 J. Huffman						
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, vides for continued examination of an utility or plant application filed on or after June 8, 1995.	Examiner Name							
See The American Inventors Protection Act of 1999 (AIPA).	Attorney Docket Number	01272.020610						

	continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.								
1.	Submission required under 37 C.F.R. § 1.114								
	a.	a. X Previously submitted							
ļ		i.	Consider the amendment(s)/reply under 37 C	nent(s)/reply under 37 C.F.R. § 1.116 previously filed on <u>September 30, 2005.</u>					
		ii.	Consider the arguments in the Appeal Brief or Reply Brief previously filed on						
		iii.	U Other:	☐ Other:					
	b.	Ш	Enclosed	10/28/2005 SZEWDIE1 00000047 10622479					
		i. ii.	Amendment/Reply Affidavit(s)/Declaration(s)		FC:1801	790.00 OP 120.00 OP			
		iii.	Information Disclosure Statement (IDS)	02	FC:1251	ILVIVO DI			
		iv.	Other:						
2:	Mi	scellar	neous						
ì	a.	Ш	Suspension of action on the above-identified applic	•		' '			
1	months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) b. X Other: Applicant petitions the Examiner to extend the time for response to the Final Office Action dated June 30.								
	b. LXJ Other: Applicant petitions the Examiner to extend the time for response to the Final Office Action dated June 30, 2005, for one month from September 30, 2005, up to and including October 30, 2005, and submits \$120.00.								
3.	Fe	es	The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.						
	a.	X	The Director is hereby authorized to charge any deficiencies in the following fees, or credit any overpayments, to						
		i.	Deposit Account No. 06-1205 RCE fee required under 37 C.F.R. § 1.17(e)						
		ii.	Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)						
		iii.							
	b. LX_I Checks in the amounts of \$790.00 and \$120.00 are enclosed to cover the RCE filing fee and extension of time fee, respectively.								
	c. Payment by credit card (Form PTO-2038 enclosed)								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED									
Nan (<i>Prir</i>		ре)	Mark A. Williamson	Registratio	n No. (Attorney/Agent)	33,628			
Sign	atur	e	Made don	Date	October 27, 2005				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

MAW/agm